

## SAFETY DATA SHEETS

**This SDS packet was issued with item:**

078907777

**The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).**

078501058 078507991 078694640 078907776 078907778

## SAFETY DATA SHEET

**Product Name: Carboplatin Injection**

### 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

<b>Manufacturer Name And Address</b>	Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA	Hospira Australia Pty Ltd 1 Lexia Place Mulgrave VIC 3170 AUSTRALIA
<b>Emergency Telephone</b>	CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418	
<b>Hospira, Inc., Non-Emergency</b>	224 212-2000	
<b>Material Name</b>	Carboplatin Injection	
<b>Synonyms</b>	Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Paraplatin	

### 2. HAZARD(S) IDENTIFICATION

<b>Emergency Overview</b>	Carboplatin Injection is a solution containing carboplatin, an analog of cisplatin with similar actions and uses. It is used alone or combined with other antineoplastics to treat some types of cancers. It is cytotoxic, neurotoxic, and in the workplace, should be considered a potential sensitizer and a potential occupational reproductive hazard. Based on clinical use, possible target organs may include the gastrointestinal tract, bone marrow, liver, kidneys, ears (hearing), and nervous system.
---------------------------	---

#### U.S. OSHA GHS Classification

Physical Hazards	Hazard Class	Hazard Category
	Not Classified	Not Classified
Health Hazards	Hazard Class	Hazard Category
	Sensitization – Respiratory	1
	Sensitization – Skin	1
	Germ Cell Mutagenicity	2
	Toxic to Reproduction	2
	STOT - RE	2

#### Label Element(s)

**Pictogram**



**Signal Word**

Danger

**Hazard Statement(s)**

May cause allergy or asthma symptoms or breathing difficulties if inhaled  
May cause an allergic skin reaction  
Suspected of causing genetic defects  
Suspected of damaging fertility or the unborn child  
May cause damage to organs through prolonged or repeated exposure

## 2. HAZARD(S) IDENTIFICATION: continued

### Precautionary Statement(s)

#### Prevention

Obtain special instructions before use.  
Do not handle until all safety precautions have been read and understood.  
Wear protective gloves/protective clothing/eye protection/face protection.  
Do not breathe vapor or spray.  
In case of inadequate ventilation, wear respiratory protection  
Contaminated work clothing must not be allowed out of the workplace  
Wash hands thoroughly after handling.

#### Response

Get medical attention if you feel unwell.  
  
IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing. If experiencing respiratory symptoms: Call a doctor.  
  
IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice/attention. Wash contaminated clothing before reuse.  
  
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Ingredient Name** Carboplatin  
**Chemical Formula**  $C_6H_{12}N_2O_4$  Pt

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Carboplatin	1	41575-94-4	TP2300000

Non hazardous ingredients include Water for Injection.

## 4. FIRST AID MEASURES

**Eye Contact** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin Contact** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Ingestion** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

## 5. FIRE FIGHTING MEASURES

**Flammability** None anticipated for this aqueous product.

**Fire & Explosion Hazard** None anticipated for this aqueous product.

**Extinguishing Media** As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam.

**Special Fire Fighting Procedures** No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

**Spill Cleanup and Disposal** Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill control procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.

## 7. HANDLING AND STORAGE

**Handling** Carboplatin is a cytotoxic agent. Appropriate procedures should be implemented during the handling and disposal of cytotoxic antineoplastics agents to minimize potential exposures. Several guidelines on handling cytotoxic antineoplastic agents have been published. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. Consult your hygienist or safety professional for your site requirements.

Avoid ingestion, inhalation, skin contact, and eye contact. The use of disposable gloves and respiratory protection is recommended. Proper disposal of contaminated vials, syringes, or other materials is required when working with this material.

**Storage** No special storage is required for hazard control. However, employees should be trained on the proper storage procedures for antineoplastic agents. For product protection, follow storage recommendations noted on the product case label or the primary container label.

**Special Precautions** Persons with known allergies to platinum compounds, women who are pregnant, or women who want to become pregnant, should consult a health and/or safety professional prior to handling this material.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Exposure Guidelines

Component	Exposure Limits			
	OSHA-PEL	ACGIH-TLV	AIHA WEEL	Hospira EEL
Carboplatin	8-hr TWA: 0.002 mg/m <sup>3</sup> for platinum, for soluble salts.	8-hr TWA: 0.002 mg/m <sup>3</sup> for platinum, for soluble salts.	8-hr TWA: Not Established	8-hr TWA: Not Established

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit  
 ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.  
 AIHA WEEL: Workplace Environmental Exposure Level  
 EEL: Employee Exposure Limit.  
 TWA: 8-hour Time Weighted Average.

**Respiratory Protection** Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols or vapors is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N99 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

**Skin Protection** When handling this material, disposable gloves should be worn at all times. Further, the use of double gloves is recommended. Disposable gloves made from nitrile, neoprene, polyurethane or natural latex generally have low permeability to chemotherapy agents. Persons known to be allergic to latex rubber should select a non-latex glove. Gloves should be changed regularly, and removed immediately after known contamination. Care should be taken to minimize inadvertent contamination when removing and/or disposing of gloves.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION: continued

<b>Eye Protection</b>	As a minimum, the use of chemical safety goggles is recommended when handling this material.
<b>Engineering Controls</b>	If handling a dry powder, local exhaust ventilation is recommended to minimize employee exposure. The use of an enclosure, such as an approved ventilated cabinet designed to minimize airborne exposures, is recommended.

## 9. PHYSICAL/CHEMICAL PROPERTIES

<b>Appearance/Physical State</b>	Sterile, clear aqueous solution in a vial
<b>Odor</b>	Odorless
<b>Odor Threshold</b>	NA
<b>pH</b>	5-7 for a 1% solution
<b>Melting point/Freezing Point</b>	NA
<b>Initial Boiling Point/Boiling Point Range</b>	NA
<b>Flash Point</b>	NA
<b>Evaporation Rate</b>	NA
<b>Flammability (solid, gas)</b>	NA
<b>Upper/Lower Flammability or Explosive Limits</b>	NA
<b>Vapor Pressure</b>	NA
<b>Vapor Density (Air =1)</b>	NA
<b>Relative Density</b>	NA
<b>Solubility</b>	Soluble in water at a rate of approximately 14 mg/mL. Virtually insoluble in ethanol, acetone, and dimethylacetamide
<b>Partition Coefficient: n-octanol/water</b>	NA
<b>Auto-ignition Temperature</b>	NA
<b>Decomposition Temperature</b>	NA
<b>Viscosity</b>	NA

## 10. STABILITY AND REACTIVITY

<b>Reactivity</b>	Not determined.
<b>Chemical Stability</b>	Stable under standard use and storage conditions.
<b>Hazardous Reactions</b>	Not determined
<b>Conditions to Avoid</b>	Not determined
<b>Incompatibilities</b>	Platinum therapeutic agents are reported to be incompatible with oxidizing agents of aluminum, sodium bicarbonate, sodium bisulfate, and sodium metabisulfite. Avoid contact with chloride salts.
<b>Hazardous Decomposition Products</b>	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx), nitrogen oxides (NOx), and oxides of platinum.
<b>Hazardous Polymerization</b>	Not anticipated to occur with this product.

## 11. TOXICOLOGICAL INFORMATION

**Acute Toxicity** - Not determined for the product formulation. Information for the active ingredient is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Carboplatin	100	LD50	Oral	343	mg/kg	Rat
Carboplatin	100	LD50	Intravenous	61	mg/kg	Rat
				89.4	mg/kg	Mouse
				31.2	mg/kg	Dog
Carboplatin	100	LD50	Intraperitoneal	118	mg/kg	Mouse
				72	mg/kg	Rat

LD50 is the dosage producing 50% mortality

### Occupational Exposure Potential

There are scientific studies that suggest that personnel (e.g. nurses, pharmacists, etc.) who prepare and administer parenteral antineoplastics (e.g. in hospitals) may be at some risk due to potential mutagenicity, teratogenicity, and/or carcinogenicity of these materials if workplace exposures are not properly controlled. The actual risk in the workplace is not known. Avoid liquid aerosol generation and skin contact.

### Signs and Symptoms

None anticipated from normal handling of this material. In the workplace, platinum compounds have been reported to cause allergic skin and respiratory reactions. This material should be considered irritating to the skin, eyes, and respiratory tract. In clinical use, adverse effects have included severe nausea and vomiting, toxic effects on the kidneys, bone marrow depression, loss of hearing, and neurological effects such as peripheral neuropathies.

### Aspiration Hazard

None anticipated from normal handling of this material.

### Dermal Irritation/Corrosion

None anticipated from normal use of this product. However, inadvertent skin contact with this product may produce redness and discomfort.

### Ocular Irritation/Corrosion

None anticipated from normal use of this product. However, inadvertent eye contact with this product may produce irritation, redness and discomfort.

### Dermal or Respiratory Sensitization

In the workplace, platinum compounds have been reported to cause allergic skin and respiratory reactions. Hypersensitivity reactions, sometimes severe, have been reported during the clinical use of this product. Persons with known allergies to platinum should consult a health or safety professional prior to handling open containers of this material.

### Reproductive Effects

None anticipated from normal handling of this material. Carboplatin has been shown to be embryotoxic and teratogenic in rats receiving the drug during organogenesis. Administration of carboplatin to male and female rats at dosages up to 4 mg/kg produced suppression of body weight in the adults and other signs of toxicity, but did not appear to impair fertility. Fetal mortality was increased, and there were decreases in intrauterine growth and skeletal ossification, consistent with general toxicity, but no increase in birth defects. In a subsequent study, when the dosage was increased to 6 mg/kg/day, an increase in congenital anomalies, including gastroschisis, ventriculomegaly, and skeletal anomalies, was noted. Carboplatin may cause fetal harm when given to pregnant women. FDA Pregnancy Category D.

### Mutagenicity

Carboplatin is genotoxic in both *in vitro* and *in vivo* mutagenesis assays, including the Ames bacterial cell assay, the Chinese hamster ovary cell assay, and the mouse lymphoma assay.

### Carcinogenicity

The carcinogenic potential of carboplatin has not been fully evaluated. By analogy, compounds with similar mechanisms of action and mutagenic potential, such as cisplatin, are considered potential human carcinogens.

## 11. TOXICOLOGICAL INFORMATION: continued

<b>Carcinogen Lists</b>	<b>IARC:</b> Not listed	<b>NTP:</b> Not listed	<b>OSHA:</b> Not listed
<b>Specific Target Organ Toxicity – Single Exposure</b>	NA		
<b>Specific Target Organ Toxicity – Repeat Exposure</b>	Based on clinical use, possible target organs may include the gastrointestinal tract, bone marrow, liver, kidneys, ears (hearing), and nervous system.		

## 12. ECOLOGICAL INFORMATION

<b>Aquatic Toxicity</b>	Not determined for product.
<b>Persistence/ Biodegradability</b>	Not determined for product.
<b>Bioaccumulation</b>	Not determined for product.
<b>Mobility in Soil</b>	Not determined for product.

Notes:

## 13. DISPOSAL CONSIDERATIONS

<b>Waste Disposal</b>	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
<b>Container Handling and Disposal</b>	Dispose of container and unused contents in accordance with federal, state and local regulations.

## 14. TRANSPORTATION INFORMATION

<b>ADR/ADG/ DOT STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA
<b>ICAO/IATA STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA
<b>IMDG STATUS</b>	Not regulated
<b>Proper Shipping Name</b>	NA
<b>Hazard Class</b>	NA
<b>UN Number</b>	NA
<b>Packing Group</b>	NA
<b>Reportable Quantity</b>	NA

Notes: DOT - US Department of Transportation Regulations

## 15. REGULATORY INFORMATION

<b>US TSCA Status</b>	Exempt
<b>US CERCLA Status</b>	Not listed
<b>US SARA 302 Status</b>	Not listed
<b>US SARA 313 Status</b>	Not listed
<b>US RCRA Status</b>	Not listed
<b>US PROP 65 (Calif.)</b>	This product is, or contains a chemical(s) known to the State of California to cause developmental toxicity.

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

### GHS/CLP Classification\*

\*In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user.

Hazard Class	Hazard Category	Pictogram	Signal Word	Hazard Statement
NA	NA	NA	NA	NA

#### **Prevention**

Obtain special instructions before use.  
Do not handle until all safety precautions have been read and understood.  
Wear protective gloves/protective clothing/eye protection/face protection.  
Do not breathe vapor or spray.  
In case of inadequate ventilation, wear respiratory protection  
Contaminated work clothing must not be allowed out of the workplace  
Wash hands thoroughly after handling.

#### **Response**

Get medical attention if you feel unwell.  
  
IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing. If experiencing respiratory symptoms: Call a doctor.  
  
IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice/attention. Wash contaminated clothing before reuse.  
  
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention.

### EU Classification\*

\*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive.

**Classification(s)**  
**Symbol**  
**Indication of Danger**

NA  
NA  
NA

#### **Risk Phrases**

R42/43: May cause sensitization by inhalation and skin contact

#### **Safety Phrases**

S23: Do not breathe vapor/spray  
S24: Avoid contact with the skin  
S25: Avoid contact with eyes  
S37/39 Wear suitable gloves and eye/face protection.



## 16. OTHER INFORMATION

Notes: NA

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD <sub>50</sub>	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
STOT - SE	Specific Target Organ Toxicity – Single Exposure
STOT - RE	Specific Target Organ Toxicity – Repeated Exposure
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS  
 Date Prepared: October 17, 2012  
 Date Revised: June 02, 2014

### Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.